Tag: next generation sequencing

FDA-Approved MI Cancer Seek Test Enhances Tumor Profiling for Precision Oncology

August 15, 2025

“Accordingly, MI Cancer Seek represents a safe and effective comprehensive molecular test option supporting biomarker-directed care for oncology patients.” BUFFALO, NY - August 15, 2025 – A new research paper… read more

Oncotarget

Study Identifies Key Genetic Alterations and Biomarker for Blastic Plasmacytoid Dendritic Cell Neoplasm

July 7, 2025

“Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.” BUFFALO,… read more

Figure 8: Major analytical performance measurements of the NeXT Personal® assay.

Oncotarget

Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal®

March 20, 2024

“These results suggest strong potential for clinical use of the assay in ctDNA monitoring of solid tumor cancers.” BUFFALO, NY- March 20, 2024 – A new research paper was published… read more

Figure 4: Correlation matrix with numerous significant positive correlations.

Oncotarget

Genetic and Therapeutic Landscapes in Cohort of Pancreatic Adenocarcinomas Using NGS and Machine Learning

February 14, 2024

“Our study was designed to build specific mutational and therapeutic landscapes of pancreatic cancer among the Russian population.” BUFFALO, NY- February 14, 2024 – A new research paper was published… read more

Figure 2: The spectrum of pathogenic variants in the early-onset breast cancer cohort.

Oncotarget

Genetic Predisposition to Early Breast Cancer in Kazakh Women

November 22, 2023

“Our study may reveal previously uncharacterized population-specific variants that may increase the risk of BC in the Kazakh population.” BUFFALO, NY- November 22, 2023 – A new research paper was… read more

Figure 2: (A) Axial T2 MR shows a heterogeneous mass in the cardiophrenic space with evidence of anterior chest wall invasion and intercostal invasion. (B) Axial T2 MR shows 35 % of reduction in size of the synovial sarcoma mass in the cardiophrenic space.

Oncotarget

Case Report: Intrathoracic Synovial Sarcoma With BRAF V600E Mutation

July 18, 2023

“The prognosis of recurrent/metastatic SS remains poor, highlighting the need for a novel therapeutic strategy.” BUFFALO, NY- July 18, 2023 – A new case report was published in Oncotarget's Volume… read more

Figure 2: Polyclonal, Clonal and Restricted Repertoire Phenotypes in Clonality Testing.

Oncotarget

Automated, Accurate Reporting for NGS-Based Clonality Testing

May 16, 2023

“[...] we have developed a fully automated calling algorithm for determining B and T cell clonality from NGS [next-generation sequencing] data, with greater sensitivity than previously developed models.” Listen to… read more